IMVT
Immunovant, Inc.
Latest Form 4:Sale$65KbyPande Atul (Director) · filed Aug 28, 2026
Immunovant, Inc. (IMVT) has 50 SEC Form 4 filings (85 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Aug 28, 2026.
The most active filer is Chief Technology Officer Stout Jay S with 9 filings. Insiders have net sold $14.2M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Eric Venker
- Employees:362
- HQ:New York City, NY, US
- IPO:2019-06-21
Insider Buying
$350.0M
reported purchases (SEC code P)
Insider Selling
$15.9M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Market Cap
$8.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 1,500 | $65K | Aug 28 | SEC ↗ | |
| Chief Operating Officer | Sale | 3,056 | $135K | Aug 21 | SEC ↗ | |
| Director | Sale | 1,500 | $60K | Jul 24 | SEC ↗ | |
| Chief Financial Officer | Sale | 6,798 | $263K | Jul 24 | SEC ↗ | |
| Chief Technology Officer | Sale | 2,857 | $111K | Jul 24 | SEC ↗ | |
| Chief Technology Officer | Sale | 3,487 | $138K | Jul 10 | SEC ↗ | |
| Chief Legal Officer | Sale | 1,206 | $48K | Jul 10 | SEC ↗ | |
| Chief Operating Officer | Sale | 2,036 | $81K | Jul 10 | SEC ↗ | |
| Chief Executive Officer | Sale | 3,092 | $119K | Jul 6 | SEC ↗ | |
| Chief Operating Officer | Sale | 17,714 | $679K | Jun 26 | SEC ↗ | |
| Chief Technology Officer | Sale | 40,000 | $1.5M | Jun 26 | SEC ↗ | |
| Chief Legal Officer | Sale | 17,824 | $683K | Jun 26 | SEC ↗ | |
| Chief Financial Officer | Sale | 10,000 | $385K | Jun 26 | SEC ↗ | |
| Director | Sale | 1,500 | $57K | Jun 26 | SEC ↗ | |
| Chief Legal Officer | Sale | 2,634 | $93K | Jun 22 | SEC ↗ | |
| Director | Sale | 1,500 | $51K | Jun 16 | SEC ↗ | |
Fromkin Andrew J.First in 6 months | Director | Sale | 221,951 | $7.4M | May 29 | SEC ↗ |
| Chief Operating Officer | Sale | 3,115 | $101K | May 22 | SEC ↗ | |
Pande AtulFirst filing | Director | Sale | 6,000 | $192K | May 21 | SEC ↗ |
Susman Robert GrahamFirst filing | Director | Sale | 2,502 | $68K | May 1 | SEC ↗ |
| Chief Technology Officer | Sale | 2,754 | $82K | Apr 24 | SEC ↗ | |
Girao TiagoFirst filing | Chief Financial Officer | Sale | 25,760 | $763K | Apr 24 | SEC ↗ |
| Chief Technology Officer | Sale | 10,132 | $252K | Apr 10 | SEC ↗ | |
| Chief Legal Officer | Sale | 5,165 | $128K | Apr 10 | SEC ↗ | |
| Chief Operating Officer | Sale | 8,722 | $217K | Apr 10 | SEC ↗ | |
| Chief Executive Officer | Sale | 14,229 | $343K | Apr 3 | SEC ↗ | |
Van Tuyl ChristopherFirst in 3 months | Chief Legal Officer | Sale | 2,877 | $72K | Mar 20 | SEC ↗ |
Gloria MelanieFirst in 3 months | Chief Operating Officer | Sale | 3,238 | $90K | Feb 27 | SEC ↗ |
| Chief Technology Officer | Sale | 1,977 | $51K | Jan 23 | SEC ↗ | |
| Chief Technology Officer | Sale | 1,203 | $32K | Jan 9 | SEC ↗ | |
Van Tuyl ChristopherFirst filing | Chief Legal Officer | Sale | 10,813 | $291K | Dec 19 | SEC ↗ |
Roivant Sciences Ltd.First filing | Director, 10% Owner | Purchase | 16,666,666 | $350.0M | Dec 12 | SEC ↗ |
Fromkin Andrew J.First filing | Director | Sale | 22,249 | $517K | Dec 3 | SEC ↗ |
Hughes Douglas J.First filing | Director | Sale | 15,000 | $349K | Dec 3 | SEC ↗ |
Gloria MelanieFirst filing | Chief Operating Officer | Sale | 12,626 | $298K | Nov 21 | SEC ↗ |
| Chief Technology Officer | Sale | 2,520 | $48K | Oct 24 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,595 | $49K | Oct 24 | SEC ↗ | |
Geffner MichaelFirst filing | Chief Medical Officer | Sale | 1,272 | $21K | Oct 10 | SEC ↗ |
Stout Jay SFirst filing | Chief Technology Officer | Sale | 1,585 | $26K | Oct 10 | SEC ↗ |
Related companies
Immunovant, Inc. is in the Healthcare sector.